AI Portfolio Summary
In 2025 Q4, Logos Global Management LP maintained a portfolio of 83 distinct positions. The most significant new addition to the portfolio was TERNS PHARMACEUTICAL, which now represents 1.83% of the total fund value. They heavily accumulated shares in REVOLUTION MEDICINES, increasing their position by 14.3%. The fund also reduced its exposure to VERASTEM INC by 58.0%.
Total Positions
83
Quarter
2025 Q4
Top Holding
RVMD (9.6%)
Top 10 Concentration
47.9%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 83
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
RVMD
REVOLUTION MEDI...
|
Healthcare | 9.63% | 7.33% |
#1
Prev: #1
|
7.9 | 250,000 | 14.3% |
P
S
|
2,000,000 | $159,300,000 | 2020 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PRAX
PRAXIS PRECISIO...
|
Healthcare | 6.68% | 0.59% |
#2
42
Prev: #44
|
7.2 | 250,000 | 200.0% |
P
S
|
375,000 | $110,527,500 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IDYA
IDEAYA BIOSCIEN...
|
Healthcare | 6.53% | 5.49% |
#3
1
Prev: #2
|
6.1 | 875,000 | 38.9% |
P
S
|
3,125,000 | $108,031,250 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OLMA
OLEMA PHARMACEU...
|
Healthcare | 4.85% | 2.82% |
#4
8
Prev: #12
|
3.4 | no change | no change |
P
S
|
3,208,875 | $80,221,875 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RVMD
CALL
REVOLUTION MEDI...
|
CALL Option | 4.81% | 4.19% |
#5
Prev: #5
|
3.4 | no change | no change |
P
S
|
1,000,000 | $79,650,000 | 2020 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CDTX
CIDARA THERAPEU...
|
Healthcare | 4.14% | 3.22% |
#6
1
Prev: #7
|
2.2 | -65,000 | -17.3% |
P
S
|
310,000 | $68,475,900 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABVX
ABIVAX SA
|
Healthcare | 3.26% | 3.16% |
#7
2
Prev: #9
|
1.8 | -15,000 | -3.6% |
P
S
|
400,000 | $53,942,000 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ERAS
ERASCA INC
|
Healthcare | 2.92% | 2.96% |
#8
2
Prev: #10
|
1.7 | -2,150,000 | -14.2% |
P
S
|
13,000,000 | $48,360,000 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OCUL
OCULAR THERAPEU...
|
Healthcare | 2.57% | 3.41% |
#9
3
Prev: #6
|
3.0 | 250,000 | 7.7% |
P
S
|
3,500,000 | $42,490,000 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 2.52% | 2.13% |
#10
9
Prev: #19
|
1.0 | -250,000 | -29.4% |
P
S
|
600,000 | $41,730,000 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IRON
DISC MEDICINE I...
|
Healthcare | 2.45% | 2.67% |
#11
4
Prev: #15
|
3.0 | 60,000 | 13.3% |
P
S
|
510,000 | $40,499,100 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MAZE
MAZE THERAPEUTI...
|
Healthcare | 2.38% | 2.85% |
#12
1
Prev: #11
|
1.0 | -277,300 | -22.6% |
P
S
|
950,000 | $39,358,500 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TNGX
TANGO THERAPEUT...
|
Healthcare | 2.25% | 0.72% |
#13
24
Prev: #37
|
3.9 | 3,250,000 | 342.1% |
P
S
|
4,200,000 | $37,212,000 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RNA
AVIDITY BIOSCIE...
|
Healthcare | 2.18% | 2.34% |
#14
4
Prev: #18
|
1.4 | -100,000 | -16.7% |
P
S
|
500,000 | $36,065,000 | 2020 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BIIB
BIOGEN INC
|
Healthcare | 2.13% | 1.26% |
#15
15
Prev: #30
|
3.9 | 100,000 | 100.0% |
P
S
|
200,000 | $35,198,000 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMVT
IMMUNOVANT INC
|
Healthcare | 2.11% | 0.40% |
#16
32
Prev: #48
|
3.8 | 1,100,000 | 400.0% |
P
S
|
1,375,000 | $34,952,500 | 2020 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JAZZ
JAZZ PHARMACEUT...
|
Healthcare | 2.05% | 2.36% |
#17
Prev: #17
|
1.8 | no change | no change |
P
S
|
200,000 | $34,000,000 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TERN
TERNS PHARMACEU...
|
Healthcare | 1.83% | — |
#18
Prev: #—
|
4.2 | 750,000 | no change |
NEW
|
750,000 | $30,300,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 1.81% | 2.02% |
#19
3
Prev: #22
|
1.2 | 25,000 | 4.0% |
P
S
|
650,000 | $29,991,000 | 2020 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMCR
IMMUNOCORE HLDG...
|
Healthcare | 1.78% | 2.77% |
#20
7
Prev: #13
|
1.7 | no change | no change |
P
S
|
850,000 | $29,503,500 | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LBRX
LB PHARMACEUTIC...
|
Healthcare | 1.61% | 1.60% |
#21
6
Prev: #27
|
2.6 | 70,000 | 6.2% |
P
S
|
1,200,000 | $26,712,000 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
APLS
CALL
APELLIS PHARMAC...
|
CALL Option | 1.52% | 2.03% |
#22
1
Prev: #21
|
1.6 | no change | no change |
P
S
|
1,000,000 | $25,120,000 | 2019 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RCUS
CALL
ARCUS BIOSCIENC...
|
CALL Option | 1.51% | — |
#23
Prev: #—
|
4.1 | 1,050,000 | no change |
NEW
|
1,050,000 | $25,021,500 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DYN
DYNE THERAPEUTI...
|
Healthcare | 1.48% | 2.72% |
#24
10
Prev: #14
|
0.6 | -1,150,000 | -47.9% |
P
S
|
1,250,000 | $24,450,000 | 2020 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DSGN
DESIGN THERAPEU...
|
Healthcare | 1.42% | 2.47% |
#25
9
Prev: #16
|
0.6 | -1,155,000 | -31.6% |
P
S
|
2,500,000 | $23,450,000 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MLTX
MOONLAKE IMMUNO...
|
Healthcare | 1.39% | — |
#26
Prev: #—
|
4.1 | 1,750,000 | no change |
NEW
|
1,750,000 | $23,065,000 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACAD
ACADIA PHARMACE...
|
Healthcare | 1.37% | — |
#27
Prev: #—
|
4.0 | 850,000 | no change |
NEW
|
850,000 | $22,703,500 | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RYTM
RHYTHM PHARMACE...
|
Healthcare | 1.23% | 1.81% |
#28
5
Prev: #23
|
1.0 | -10,000 | -5.0% |
P
S
|
190,000 | $20,337,600 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TRVI
TREVI THERAPEUT...
|
Healthcare | 1.17% | 1.80% |
#29
5
Prev: #24
|
0.5 | -650,000 | -29.5% |
P
S
|
1,550,000 | $19,406,000 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYTK
CYTOKINETICS IN...
|
Healthcare | 1.15% | — |
#30
Prev: #—
|
4.0 | 300,000 | no change |
NEW
|
300,000 | $19,062,000 | 2020 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MIRM
MIRUM PHARMACEU...
|
Healthcare | 1.07% | — |
#31
Prev: #—
|
3.9 | 225,000 | no change |
NEW
|
225,000 | $17,772,750 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
QURE
UNIQURE NV
|
Healthcare | 0.98% | 1.57% |
#32
4
Prev: #28
|
3.4 | 375,000 | 125.0% |
P
S
|
675,000 | $16,152,750 | 2019 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NAMS
NEWAMSTERDAM PH...
|
Healthcare | 0.95% | — |
#33
Prev: #—
|
3.9 | 450,000 | no change |
NEW
|
450,000 | $15,786,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IDYA
CALL
IDEAYA BIOSCIEN...
|
CALL Option | 0.94% | 1.10% |
#34
Prev: #34
|
1.4 | no change | no change |
P
S
|
450,000 | $15,556,500 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KNSA
KINIKSA PHARMAC...
|
Healthcare | 0.87% | — |
#35
Prev: #—
|
3.8 | 350,000 | no change |
NEW
|
350,000 | $14,437,500 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLNO
SOLENO THERAPEU...
|
Healthcare | 0.84% | — |
#36
Prev: #—
|
3.8 | 300,000 | no change |
NEW
|
300,000 | $13,890,000 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JANX
JANUX THERAPEUT...
|
Healthcare | 0.83% | 2.05% |
#37
17
Prev: #20
|
2.3 | 65,000 | 7.0% |
P
S
|
1,000,000 | $13,800,000 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NERV
MINERVA NEUROSC...
|
Healthcare | 0.80% | — |
#38
Prev: #—
|
3.8 | 3,311,000 | no change |
NEW
|
3,311,000 | $13,310,220 | 2019 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VSTM
VERASTEM INC
|
Healthcare | 0.79% | 3.21% |
#39
31
Prev: #8
|
0.3 | -2,350,000 | -58.0% |
P
S
|
1,700,000 | $13,124,000 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DNTH
DIANTHUS THERAP...
|
Healthcare | 0.78% | 0.71% |
#40
2
Prev: #38
|
3.3 | 115,000 | 57.5% |
P
S
|
315,000 | $12,981,150 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AMLX
AMYLYX PHARMACE...
|
Healthcare | 0.69% | 1.77% |
#41
15
Prev: #26
|
0.3 | -500,000 | -34.5% |
P
S
|
950,000 | $11,476,000 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KYMR
KYMERA THERAPEU...
|
Healthcare | 0.61% | 1.27% |
#42
13
Prev: #29
|
0.2 | -120,000 | -48.0% |
P
S
|
130,000 | $10,115,300 | 2020 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CLDX
CELLDEX THERAPE...
|
Healthcare | 0.57% | — |
#43
Prev: #—
|
3.7 | 350,000 | no change |
NEW
|
350,000 | $9,506,000 | 2020 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NRIX
NURIX THERAPEUT...
|
Healthcare | 0.57% | — |
#44
Prev: #—
|
3.7 | 500,000 | no change |
NEW
|
500,000 | $9,485,000 | 2020 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMTX
CALL
IMMATICS N.V
|
CALL Option | 0.54% | — |
#45
Prev: #—
|
3.7 | 850,000 | no change |
NEW
|
850,000 | $8,925,000 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CGON
CG ONCOLOGY INC
|
Healthcare | 0.50% | — |
#46
Prev: #—
|
3.7 | 200,000 | no change |
NEW
|
200,000 | $8,304,000 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACLX
ARCELLX INC
|
Healthcare | 0.45% | 1.21% |
#47
16
Prev: #31
|
0.2 | -50,000 | -30.3% |
P
S
|
115,000 | $7,498,000 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
CRESCENT BIOPHA...
|
—
|
Unknown | 0.43% | 0.64% |
#48
7
Prev: #41
|
1.2 | no change | no change |
P
S
|
600,000 | $7,116,000 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
CMPX
COMPASS THERAPE...
|
Healthcare | 0.37% | 0.64% |
#49
9
Prev: #40
|
0.1 | -900,000 | -43.9% |
P
S
|
1,150,000 | $6,175,500 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JBIO
JADE BIOSCIENCE...
|
Healthcare | 0.37% | 0.48% |
#50
4
Prev: #46
|
0.1 | -230,000 | -36.8% |
P
S
|
395,000 | $6,094,850 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-50 of 83 holdings